The Broad Institute has recently failed to protect its CRISPR-Cas patent before the Boards of Appeal. Now the European Patent Office has maintained a rival’s basic patent for the same technology. The opponents are likely to appeal.<\/p>\n\n\n\n
Last Friday the EPO\u2019s Opposition Division dismissed the objections to EP 2 800 811 B1 <\/a>after three days of hearings. The patent was maintained in its original form. The owners, the University of California (Berkeley) and University of Vienna, and the main inventors, Jennifer Doudna and Emmanuelle Charpentier, have thus provisionally enforced their claim for protection in Europe for CRISPR-Cas technology.<\/p>\n\n\n\n Representatives:<\/strong><\/p>\n\n\n\n For the University of California For df-mp For Griebling For HGF For Jones Day USA For Pinsent Masons For Allergan Pharmaceuticals For Elkington & Fife\/Glyn Truscott European Patent Office, Opposition Division
Maiwald<\/strong> (Munich): Dirk B\u00fchler<\/a> (lead), Martin Huenges<\/a>, Kerstin Wolff<\/a>, Sarah von Leliwa<\/a> (all patent attorneys)<\/p>\n\n\n\n
df-mp D\u00f6rries Frank-Molina & Pohlman<\/strong> (Munich): Sandra Pohlman (patent attorney)<\/p>\n\n\n\n
Octrooibureau Griebling<\/strong> (Tilburg): Onno Griebling<\/p>\n\n\n\n
HGF (London)<\/p>\n\n\n\n
Jones Day<\/strong> (Munich)<\/p>\n\n\n\n
TL Brand<\/strong> (London)<\/p>\n\n\n\n
Hoffmann Eitle<\/strong> (Munich): Elisabeth Engelhard<\/p>\n\n\n\n
Greaves Brewster<\/strong> (London)<\/p>\n\n\n\n
Henrik Knudsen (Chairman), Matthias Ulbrecht, Suzanna Weinberg<\/p>\n\n\n\n